These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 29913479)

  • 1. Prioritizing and modelling of putative drug target proteins of Candida albicans by systems biology approach.
    Ismail T; Fatima N; Muhammad SA; Zaidi SS; Rehman N; Hussain I; Tariq NUS; Amirzada I; Mannan A
    Acta Biochim Pol; 2018; 65(2):209-218. PubMed ID: 29913479
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic identification of potential targets unique to Candida albicans for the discovery of antifungal agents.
    Tripathi H; Luqman S; Meena A; Khan F
    Curr Drug Targets; 2014 Jan; 15(1):136-49. PubMed ID: 24102473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prioritizing drug targets in Clostridium botulinum with a computational systems biology approach.
    Muhammad SA; Ahmed S; Ali A; Huang H; Wu X; Yang XF; Naz A; Chen J
    Genomics; 2014 Jul; 104(1):24-35. PubMed ID: 24837790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular Elucidation of Riboflavin Production and Regulation in Candida albicans, toward a Novel Antifungal Drug Target.
    Demuyser L; Palmans I; Vandecruys P; Van Dijck P
    mSphere; 2020 Aug; 5(4):. PubMed ID: 32759338
    [No Abstract]   [Full Text] [Related]  

  • 5. Development and targeting of transcriptional regulatory network controlling FLU1 activation in Candida albicans for novel antifungals.
    Jha A; Kumar A
    J Mol Graph Model; 2016 Sep; 69():1-7. PubMed ID: 27494210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigating Common Pathogenic Mechanisms between
    Yeh SJ; Yeh CC; Lan CY; Chen BS
    Toxins (Basel); 2019 Feb; 11(2):. PubMed ID: 30769958
    [No Abstract]   [Full Text] [Related]  

  • 7. Human fungal pathogen Candida albicans in the postgenomic era: an overview.
    Kabir MA; Hussain MA
    Expert Rev Anti Infect Ther; 2009 Feb; 7(1):121-34. PubMed ID: 19622061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the druggable proteome of Candida species through comprehensive computational analysis.
    Mukherjee S; Kundu I; Askari M; Barai RS; Venkatesh KV; Idicula-Thomas S
    Genomics; 2021 Mar; 113(2):728-739. PubMed ID: 33484798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large-scale essential gene identification in Candida albicans and applications to antifungal drug discovery.
    Roemer T; Jiang B; Davison J; Ketela T; Veillette K; Breton A; Tandia F; Linteau A; Sillaots S; Marta C; Martel N; Veronneau S; Lemieux S; Kauffman S; Becker J; Storms R; Boone C; Bussey H
    Mol Microbiol; 2003 Oct; 50(1):167-81. PubMed ID: 14507372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Candida albicans growth by brominated furanones.
    Duo M; Zhang M; Luk YY; Ren D
    Appl Microbiol Biotechnol; 2010 Feb; 85(5):1551-63. PubMed ID: 19756586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New evidence that Candida albicans possesses additional ATP-binding cassette MDR-like genes: implications for antifungal azole resistance.
    Walsh TJ; Kasai M; Francesconi A; Landsman D; Chanock SJ
    J Med Vet Mycol; 1997; 35(2):133-7. PubMed ID: 9147273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentially-expressed genes in Candida albicans exposed to ε-poly-L-lysine.
    Ye RS; Zhang ZH; Xu HY; Xu F; Aguilar ZP; Xiong YH; Zeng ZL; Wei H
    Biotechnol Lett; 2013 Dec; 35(12):2147-53. PubMed ID: 23974498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atomic modelling and systematic mutagenesis identify residues in multiple drug binding sites that are essential for drug resistance in the major Candida transporter Cdr1.
    Nim S; Lobato LG; Moreno A; Chaptal V; Rawal MK; Falson P; Prasad R
    Biochim Biophys Acta; 2016 Nov; 1858(11):2858-2870. PubMed ID: 27569110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative genomics allowed the identification of drug targets against human fungal pathogens.
    Abadio AK; Kioshima ES; Teixeira MM; Martins NF; Maigret B; Felipe MS
    BMC Genomics; 2011 Jan; 12():75. PubMed ID: 21272313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans.
    Kim K; Zilbermintz L; Martchenko M
    Ann Clin Microbiol Antimicrob; 2015 Jun; 14():32. PubMed ID: 26054754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic Effects and Mechanisms of Budesonide in Combination with Fluconazole against Resistant Candida albicans.
    Li X; Yu C; Huang X; Sun S
    PLoS One; 2016; 11(12):e0168936. PubMed ID: 28006028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of potential inhibitors against nuclear Dam1 complex subunit Ask1 of Candida albicans using virtual screening and MD simulations.
    Tripathi H; Khan F
    Comput Biol Chem; 2018 Feb; 72():33-44. PubMed ID: 29346071
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genome-wide expression profiling of the response to terbinafine in Candida albicans using a cDNA microarray analysis.
    Zeng YB; Qian YS; Ma L; Gu HN
    Chin Med J (Engl); 2007 May; 120(9):807-13. PubMed ID: 17531123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Candida albicans Hom6 is a homoserine dehydrogenase involved in protein synthesis and cell adhesion.
    Tsai PW; Chien CY; Yeh YC; Tung L; Chen HF; Chang TH; Lan CY
    J Microbiol Immunol Infect; 2017 Dec; 50(6):863-871. PubMed ID: 27089825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.